

BAB 5

KESIMPULAN

5.1 Kesimpulan

Berdasarkan dari literatur review pada 9 artikel ilmiah terkait efektivitas dan efek samping penggunaan kombinasi Simvastatin dan Ezetimibe pada Dislipidemia dapat disimpulkan bahwa:

1. Penggunaan kombinasi Simvastatin 1x40 mg dan Ezetimibe 1x10 mg yang dikonsumsi peroral pada pasien dislipidemia dengan maupun tanpa komplikasi ACS efektif jika ditinjau dari penurunan kadar LDL-C 44,1% dan penurunan Trigliserida 30,8% setelah 30 hari pengobatan.
2. Efek samping yang perlu diwaspadai selama penggunaan Simvastatin dan Ezetimibe adalah gangguan otot.

5.2 Saran

Berdasarkan dari literatur review pada 9 artikel ilmiah terkait efektivitas dan efek samping penggunaan kombinasi Simvastatin dan Ezetimibe pada Dislipidemia diberikan saran:

1. Perlu dilaksanakan penelitian lebih lanjut untuk mengetahui faktor resiko yang dapat memicu gangguan otot. Informasi tersebut dapat menjadi pertimbangan penting bagi Dokter dan Farmasi dalam monitoring terapi kombinasi Simvastatin dan Ezetimibe.
2. Perlu dilaksanakan kajian literatur dengan memperluas database yang digunakan sehingga artikel yang digunakan dapat semakin banyak.

3. Perlu dilaksanakan meta analisa untuk melihat signifikansi hasil dari beberapa penelitian dengan karakteristik maupun luaran hasil yang sama untuk mendapatkan kesimpulan lebih objektif mengenai profil efektivitas dan keamanan penggunaan kombinasi Simvastatin dengan Ezetimibe.

DAFTAR PUSTAKA

- Abdel-Kareem, A., Kabbash, I., Saied, S., & Al-Deeb, A. (2019). Knowledge, practices and attitudes of physicians towards evidence-based medicine in Egypt. *Eastern Mediterranean Health Journal*, **25**(2), 82–89.
- Apostolopoulou, M., Corsini, A., & Roden, M. (2015). The role of mitochondria in statin-induced myopathy. *European Journal of Clinical Investigation*, **45**(7), 745–754.
- Arsana, P. M., Rosandi, R., Manaf, A., Budhiarta, A., & Permana, H. (2019). Pedoman Pengelolaan Dislipidemi di Indonesia 2019. *Pb. Perkeni*, 9.
- Bach, R. G., Cannon, C. P., Giugliano, R. P., White, J. A., Lokhnygina, Y., Bohula, E. A., Califf, R. M., Braunwald, E., & Blazing, M. A. (2019). Effect of Simvastatin-Ezetimibe Compared with Simvastatin Monotherapy after Acute Coronary Syndrome among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Cardiology*, **4**(9), 846–854.
- Baier, N. (2017). Antilocality and Antiagreement. *Linguistic Inquiry*, **48**(2), 367–377.
- Bays, H. E., Neff, D., Tomassini, J. E., & Tershakovec, A. M. (2008). Ezetimibe: Cholesterol lowering and beyond. *Expert Review of Cardiovascular Therapy*, **6**(4), 447–470.
- Bohula, E. A., Giugliano, R. P., Cannon, C. P., Zhou, J., Murphy, S. A., White, J. A., Tershakovec, A. M., Blazing, M. A., & Braunwald, E. (2015). Achievement of dual low-density lipoprotein cholesterol and high-sensitivity c-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. *Circulation*, **132**(13), 1224–1233.
- Brown, W. V., Foody, J. M., Zieve, F. J., Tomassini, J. E., Shah, A., & Tershakovec, A. M. (2016). Inverse relationship between

high-density lipoprotein cholesterol raising and high-sensitivity C-reactive protein reduction in older patients treated with lipid-lowering therapy. *Journal of Clinical Lipidology*, **10(1)**, 116–123.

Cannon, C. P., Mbbs, A. T., Tershakovec, A. M., Lokhnygina, Y., Jennifer, A., Ms, W., Reist, C., Bs, A. M., Braunwald, E., A, M. T., M, T. A., Yuliya, L., & A, W. J. (2016). On-Treatment Analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). *American Heart Journal*.

Chan, P., Shao, L., Tomlinson, B., Zhang, Y., & Liu, Z. M. (2019). An evaluation of pitavastatin for the treatment of hypercholesterolemia. *Expert Opinion on Pharmacotherapy*, **20(1)**, 103–113.

Cortese, F., Gesualdo, M., Cortese, A., Carbonara, S., Devito, F., Zito, A., Ricci, G., Scicchitano, P., & Ciccone, M. M. (2016). Rosuvastatin: Beyond the cholesterol-lowering effect. *Pharmacological Research*, **107**, 1–18.

Florentin, M., Liberopoulos, E. N., & Elisaf, M. S. (2008). Ezetimibe-associated adverse effects: What the clinician needs to know. *International Journal of Clinical Practice*, **62(1)**, 88–96.

Florentin, Matilda, & Elisaf, M. S. (2012). Simvastatin interactions with other drugs. *Expert Opinion on Drug Safety*, **11(3)**, 439–444.

Genest, J. (2006). Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. *Canadian Journal of Cardiology*, **22(10)**, 863–868.

Goswami, S., As, V., Bhunia, B., & Mandal, T. (2012). A review on lovastatin and its production. *Journal of Biochemical Technology*, **4(1)**, 581–587.

- Grigore, L., Raselli, S., Garlaschelli, K., Redaelli, L., Norata, G. D., Pirillo, A., & Catapano, A. L. (2013). Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. *European Journal of Clinical Pharmacology*, **69**(3), 341–346.
- Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., De Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., ... Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. In *Circulation* (Vol. 139, Issue 25).
- Gryn, S. E., & Hegele, R. A. (2015). Ezetimibe plus simvastatin for the treatment of hypercholesterolemia. *Expert Opinion on Pharmacotherapy*, **16**(8), 1255–1262.
- Hernandez-Mijares, A., Bañuls, C., Rovira-Llopis, S., Diaz-Morales, N., Escribano-Lopez, I., de Pablo, C., Alvarez, A., Veses, S., Rocha, M., & Victor, V. M. (2016). Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hypercholesterolemia. *Atherosclerosis*, **247**, 40–47.
- Hwang, S. D., Lee, J. H., Jhee, J. H., Kim, Y. J., Park, K. M., Kim, J. K., Lee, S. W., & Song, J. H. (2019). Effect of Fluvastatin on Cardiovascular Complications in Kidney Transplant Patients: A Systemic Review and Meta-analysis. *Transplantation Proceedings*, **51**(8), 2710–2713.
- Kasichayanula, S., Grover, A., Emery, M. G., Gibbs, M. A., Somaratne, R., Wasserman, S. M., & Gibbs, J. P. (2018). Clinical Pharmacokinetics and Pharmacodynamics of

Evolocumab, a PCSK9 Inhibitor. *Clinical Pharmacokinetics*, **57(7)**, 769–779.

Kato, E. T., Cannon, C. P., Blazing, M. A., Bohula, E., Guneri, S., White, J. A., Murphy, S. A., Park, J. G., Braunwald, E., & Giugliano, R. P. (2017). Efficacy and safety of adding ezetimibe to statin therapy among women and men: Insight from IMPROVE-IT (improved reduction of outcomes: Vytorin efficacy international trial). *Journal of the American Heart Association*, **6(11)**, 1–10.

Kei, A. A., Filippatos, T. D., & Elisaf, M. S. (2016). The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. *Expert Opinion on Drug Safety*, **15(4)**, 559–569.

Kementerian Kesehatan Republik Indonesia. (2017). Buku Panduan Penilaian Teknologi Kesehatan. *Jakarta: Kementerian Kesehatan Republik Indonesia*, 118–120.

Lee, J. H., Shin, D. H., Kim, B. K., Ko, Y. G., Choi, D., Jang, Y., & Hong, M. K. (2016). Early effects of intensive lipid-lowering treatment on plaque characteristics assessed by virtual histology intravascular ultrasound. *Yonsei Medical Journal*, **57(5)**, 1087–1094.

Leen, B., Bel, M., & McQuillan, P. (2014). *Evidence-Based Practice : A Practice Manual*.
<http://hdl.handle.net/10147/317326>

Lennern, H. (2003). of Atorvastatin. *Clinical Pharmacokinetics*, **42(13)**, 1141–1160.

Lin, H., & Zhang, Y. ming. (2017). The effect of Ezetimibe and Simvastatin Combination Therapy on percutaneous coronary intervention patients. *International Journal of Cardiology*, **242**, 1–3.

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V.,

- Ference, B. A., Graham, I. M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T. R., Riccardi, G., Richter, D. J., Sabatine, M. S., Taskinen, M. R., ... Patel, R. S. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. *European Heart Journal*, **41**(1), 111–188.
- Magnavita, M., Garcia, O., Varela, C. G., Silva, P. F., Roberto, P., Lima, P., Góes, P. M., Rodrigues, M. G., Lourdes, M. De, Souza, L., Marice, A., Ladeia, T., Guimarães, A. C., Claudio, L., & Correia, L. (2015). *Original Article Endothelial Effect of Statin Therapy at a High Dose Versus Low Dose Associated with Ezetimibe*. 279–288.
- Mancini, G. B. J., Tashakkor, A. Y., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D. S., Pearson, G. J., & Pope, J. (2013). Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian working group consensus update. *Canadian Journal of Cardiology*, **29**(12), 1553–1568.
- Mendes, P., Robles, P. G., & Mathur, S. (2014). Statin-induced rhabdomyolysis: A comprehensive review of case reports. *Physiotherapy Canada*, **66**(2), 124–132.
- Moayyedi, P., & Hunt, R. H. (2014). Randomized Controlled Trials. *GI Epidemiology: Diseases and Clinical Methodology: Second Edition*, **7**, 113–118.
- Murad, M. H., Asi, N., Alsawas, M., & Alahdab, F. (2016). New evidence pyramid. *Evidence-Based Medicine*, **21**(4), 125–127.
- Pedersen, T. R., & Tobert, J. A. (2004). *Simvastatin : a review*. November 1994, 2583–2596.
- Phan, B. A. P., Dayspring, T. D., & Toth, P. P. (2012). Ezetimibe therapy: Mechanism of action and clinical update. *Vascular Health and Risk Management*, **8**(1), 415–427.
- Pizzini, A., Lunger, L., Demetz, E., Hilbe, R., Weiss, G.,

- Ebenbichler, C., & Tancevski, I. (2017). The role of omega-3 fatty acids in reverse cholesterol transport: A review. *Nutrients*, **9**(10).
- Rahayu, T., Syafril, S., Wekke, I. S., & Erlinda, R. (2019). *Teknik Menulis Review Literatur Dalam Sebuah Artikel Ilmiah*. September.
- Ramkumar, S., Raghunath, A., & Raghunath, S. (2016). Statin therapy: Review of safety and potential side effects. *Acta Cardiologica Sinica*, **32**(6), 631–639.
- Rhee, E., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, H. J., Choi, S., Moon, M. K., Na, J. O., Park, K., Oh, M. S., Han, S. Y., Noh, J., Yi, K. H., Lee, S., Hong, S., & Jeong, I. (2019). 2018 Guidelines for the management of dyslipidemia Cardiovascular disease in Koreans. *Korean Journal of Internal Medicine*, **34**(4), 723–771.
- Robinson, J. G. (2007). Simvastatin: Present and future perspectives. *Expert Opinion on Pharmacotherapy*, **8**(13), 2159–2127.
- Siswanto, S. (2012). Systematic Review Sebagai Metode Penelitian Untuk Mensintesis Hasil-Hasil Penelitian (Sebuah Pengantar). *Buletin Penelitian Sistem Kesehatan*, **13**(4).
- Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. *Journal of Business Research*, **104**(March), 333–339.
- Suzuki, H., Watanabe, Y., Kumagai, H., & Shuto, H. (2013). Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. *Therapeutic Advances in Cardiovascular Disease*, **7**(6), 306–315.
- Tarantino, N., Santoro, F., De Gennaro, L., Correale, M., Guastafierro, F., Gaglione, A., Di Biase, M., & Brunetti, N. D. (2017). Fenofibrate/simvastatin fixed-dose combination in the

treatment of mixed dyslipidemia: Safety, efficacy, and place in therapy. *Vascular Health and Risk Management*, **13**, 29–41.

- Tebala, G. D. (2018). The emperor's new clothes: A critical appraisal of evidence-based medicine. *International Journal of Medical Sciences*, **15**(12), 1397–1405.
- Tuteja, S. (2019). Activation of HCAR2 by niacin: Benefits beyond lipid lowering. *Pharmacogenomics*, **20**(16), 1143–1150.
- Ward, N. C., Watts, G. F., & Eckel, R. H. (2019). Statin Toxicity: Mechanistic Insights and Clinical Implications. *Circulation Research*, **124**(2), 328–350.
- Weng, T. C., Yang, Y. H. K., Lin, S. J., & Tai, S. H. (2010). A systematic review and meta-analysis on the therapeutic equivalence of statins. *Journal of Clinical Pharmacy and Therapeutics*, **35**(2), 139–151.
- Zhan, S., Tang, M., Liu, F., Xia, P., Shu, M., & Wu, X. (2018). Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. *Cochrane Database of Systematic Reviews*, **2018**(11).